Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer

[1]  T. Curiel,et al.  Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study , 2021, Journal for ImmunoTherapy of Cancer.

[2]  E. Julián,et al.  Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG , 2021, Frontiers in Immunology.

[3]  Kazumasa Matsumoto,et al.  Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study , 2020, BMC Urology.

[4]  J. Chan,et al.  Underestimated Manipulative Roles of Mycobacterium tuberculosis Cell Envelope Glycolipids During Infection , 2019, Front. Immunol..

[5]  T. Curiel,et al.  Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial , 2019, Oncoimmunology.

[6]  G. Beamer,et al.  Selective delipidation of Mycobacterium bovis BCG enables direct pulmonary vaccination and enhances protection against Mycobacterium tuberculosis , 2019, Mucosal Immunology.

[7]  J. Miyazaki,et al.  Bacillus Calmette–Guérin strain differences as the basis for immunotherapies against bladder cancer , 2018, International journal of urology : official journal of the Japanese Urological Association.

[8]  Jianhua Ruan,et al.  Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer , 2018, Oncotarget.

[9]  J. Keane,et al.  Phenolic Glycolipid Facilitates Mycobacterial Escape from Microbicidal Tissue-Resident Macrophages , 2017, Immunity.

[10]  J. Cornell,et al.  Efficacy of bacillus Calmette‐Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta‐Analysis , 2017, The Journal of urology.

[11]  D. Minnikin,et al.  The role of hydrophobicity in tuberculosis evolution and pathogenicity , 2017, Scientific Reports.

[12]  P. Constant,et al.  Trisaccharides of Phenolic Glycolipids Confer Advantages to Pathogenic Mycobacteria through Manipulation of Host-Cell Pattern-Recognition Receptors. , 2016, ACS chemical biology.

[13]  Jun Liu,et al.  Loss of Lipid Virulence Factors Reduces the Efficacy of the BCG Vaccine , 2016, Scientific Reports.

[14]  Jonathan Izawa,et al.  Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE) , 2016, Bladder cancer.

[15]  J. Mittler,et al.  Mycobacterium tuberculosis Strains Lacking Surface Lipid Phthiocerol Dimycocerosate Are Susceptible to Killing by an Early Innate Host Response , 2014, Infection and Immunity.

[16]  J. Errington,et al.  Bacterial Cell Morphogenesis Does Not Require a Preexisting Template Structure , 2014, Current Biology.

[17]  A. Tyagi,et al.  Secretory Phosphatases Deficient Mutant of Mycobacterium tuberculosis Imparts Protection at the Primary Site of Infection in Guinea Pigs , 2013, PloS one.

[18]  A. Zlotta,et al.  The management of BCG failure in non-muscle-invasive bladder cancer: an update. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[19]  M. Albert,et al.  Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer , 2012, Science Translational Medicine.

[20]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[21]  André Lopez,et al.  Phthiocerol Dimycocerosates of M. tuberculosis Participate in Macrophage Invasion by Inducing Changes in the Organization of Plasma Membrane Lipids , 2009, PLoS pathogens.

[22]  E. R. Rhoades,et al.  In Vivo Activity of Released Cell Wall Lipids of Mycobacterium bovis Bacillus Calmette-Guérin Is Due Principally to Trehalose Mycolates1 , 2005, The Journal of Immunology.

[23]  M. Reed,et al.  A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response , 2004, Nature.

[24]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[25]  R. Sylvester,et al.  Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. , 2001, The Journal of urology.

[26]  J. Gerdes,et al.  The fate of bacillus Calmette-Guerin after intravesical instillation. , 2001, The Journal of urology.

[27]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[28]  T. Suzutani,et al.  Role of gamma delta TCR+ lymphocytes in the augmented resistance of trehalose 6,6'-dimycolate-treated mice to influenza virus infection. , 1997, The Journal of general virology.

[29]  W. Catalona,et al.  T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. , 1993, The Journal of urology.

[30]  C. L. Silva,et al.  Role of cord factor in the modulation of infection caused by mycobacteria. , 1985, The American journal of pathology.

[31]  A. Böhle,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.